Key Takeaways
- • Hatteras Venture Partners closed $207 million across two funds in summer 2025 ($177 million for its seventh core fund and $30 million for its inaugural Opportunity Fund)—the firm's largest capital raise in 25 years, demonstrating institutional confidence in North Carolina's biotech ecosystem despite macro headwinds.
- • Healthcare venture funding collapsed 78% year-over-year, with only $5 billion raised in H1 2025 versus $23 billion across all of 2024 (PitchBook data), making Hatteras's capital raise a contrarian signal of regional strength and investor selectivity.
- • North Carolina's Research Triangle ranks third nationally for life sciences employment with 75,000+ workers and concentrates NIH funding, academic research output, and biomanufacturing capacity comparable only to Boston and the Bay Area.
- • Cape Fear BioCapital, a new seed-stage therapeutics fund, deployed initial investments into Duke University spinouts, signaling emergence of layered investment infrastructure beyond institutional venture players.
- • Capital availability has historically been the Triangle's constraint despite abundant talent and infrastructure; current momentum suggests a structural shift toward local institutional investment in life sciences.
Summary
North Carolina's Research Triangle has long functioned as a quiet biotech powerhouse anchored by Raleigh, Durham, and Chapel Hill, but its investment landscape is undergoing a notable transformation. The region ranks third nationally for life sciences employment with more than 75,000 workers and hosts concentrations of NIH funding, academic research, and biomanufacturing capacity that rival only Boston and the Bay Area. Historically, however, capital availability has remained the missing piece despite abundant talent and scientific infrastructure rooted in three major research universities: Duke University, University of North Carolina at Chapel Hill, and North Carolina State University.
Two announcements in summer 2025 signal a maturing investment climate. Durham-based Hatteras Venture Partners, the region's most prominent life sciences venture firm, closed over $200 million across two new funds—its largest capital haul in a quarter century. The firm secured $177 million for its seventh core fund and $30 million for its inaugural Opportunity Fund. This performance is particularly notable given the severe contraction in healthcare venture funding: only $5 billion was raised in the first half of 2025 compared with $23 billion across all of 2024, according to PitchBook data. Co-founder Clay Thorp stated to The Wall Street Journal that "in this environment, we feel fantastic about how we're positioned," reflecting confidence built on nearly three decades of early-stage investing and support for more than 100 portfolio companies since inception.
Complementing Hatteras's scale, Cape Fear BioCapital has emerged as a new seed-stage entrant dedicated exclusively to therapeutics development in North Carolina, with initial capital deployed into Duke University spinout companies. Together, these developments suggest the Triangle is transitioning from a pure research and talent hub into a destination for layered institutional investment infrastructure, potentially reshaping the state's innovation trajectory and attracting capital that has historically flowed to coastal biotech centers.
Two announcements in summer 2025 signal a maturing investment climate. Durham-based Hatteras Venture Partners, the region's most prominent life sciences venture firm, closed over $200 million across two new funds—its largest capital haul in a quarter century. The firm secured $177 million for its seventh core fund and $30 million for its inaugural Opportunity Fund. This performance is particularly notable given the severe contraction in healthcare venture funding: only $5 billion was raised in the first half of 2025 compared with $23 billion across all of 2024, according to PitchBook data. Co-founder Clay Thorp stated to The Wall Street Journal that "in this environment, we feel fantastic about how we're positioned," reflecting confidence built on nearly three decades of early-stage investing and support for more than 100 portfolio companies since inception.
Complementing Hatteras's scale, Cape Fear BioCapital has emerged as a new seed-stage entrant dedicated exclusively to therapeutics development in North Carolina, with initial capital deployed into Duke University spinout companies. Together, these developments suggest the Triangle is transitioning from a pure research and talent hub into a destination for layered institutional investment infrastructure, potentially reshaping the state's innovation trajectory and attracting capital that has historically flowed to coastal biotech centers.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.